Rabepra 20 mg (Capsule (Enteric Coated))

Unit Price: ৳ 8.00 (5 x 10: ৳ 400.00)

Strip Price: ৳ 80.00

Medicine Details

Category	Details
Generic	Rabeprazole sodium
Company	Euro pharma ltd
Also available as	Rabepra 20 mg tablet

Indications

Active duodenal ulcer
Active benign gastric ulcer
Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD)
Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance)
Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
Zollinger-Ellison Syndrome
In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease

Pharmacology

Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell.

Dosage

Recommended oral dose for active duodenal ulcer and active benign gastric ulcer is 20 mg once daily in the morning
Recommended oral dose for erosive or ulcerative gastro-esophageal reflux disease (GERD) is 20 mg once daily for four to eight weeks
For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response
10 mg once daily in patients without esophagitis for symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD)
5 mg once daily for pediatric patients 1 to 11 years of age weighing less than 15 kg
10 mg once daily for pediatric patients 1 to 11 years of age weighing 15 kg or more
Recommended adult starting dose for Zollinger-Ellison Syndrome is 60 mg once a day, may be titrated upwards to 120 mg/day based on patient needs
Combination therapy for eradication of H. pylori: Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1g twice daily for 7 days

Administration

Rabeprazole tablets should be taken in the morning, before eating, and should be swallowed whole.

Interaction

Potential interactions with compounds whose absorption is pH dependent, such as ketoconazole or itraconazole. No interaction with liquid antacids observed. Absorption of atazanavir is pH-dependent, hence co-administration with PPIs, including rabeprazole, should be avoided.

Contraindications

Contra-indicated in case of hypersensitivity to the active substance or to any of the excipients. Contra-indicated in pregnancy and during breastfeeding.

Side Effects

Well-tolerated in both short-term and long-term studies
May sometimes cause headache, diarrhea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness

Pregnancy & Lactation

US FDA pregnancy category 'C'. No adequate and well-controlled studies in pregnant women. Likely to be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Precautions & Warnings

Symptomatic response to therapy does not exclude the possibility of malignancy, hence malignancy should be excluded prior to treatment
Long-term treatment may modestly increase the risk of hip, wrist and spine fracture, especially in the elderly or in presence of other recognized risk factors
Risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded
Hypomagnesaemia reported in patients treated with PPIs for at least three months, may begin insidiously and be overlooked
May reduce the absorption of vitamin B12 (cyanocobalamin)
PPIs associated with very infrequent cases of subacute cutaneous lupus erythematosus
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumors, hence treatment should be stopped for at least 5 days before CgA measurements

Use in Special Populations

No dosage adjustment necessary for patients with renal or hepatic impairment
Not recommended for use in children due to a lack of data on safety and efficacy

Overdose Effects

No specific antidote known, effects generally minimal and reversible without further medical intervention, treatment should be symptomatic and general supportive measures utilized.

Therapeutic Class

Proton Pump Inhibitor

Storage Conditions

Keep below 30°C temperature, away from light & moisture, and out of the reach of children.

Chemical Structure

Molecular Formula: C18H21N3O3S
Chemical Structure Image: https://medex.com.bd/storage/res/g-res-942-rabeprazole-sodium-chemical-structure-atwg0Q4PlndQZhOY9GHX.svg

Common Questions

What is Rabepra 20 mg Capsule?
What is Rabepra 20 mg Capsule used for?
What are the side effects of Rabepra 20 mg Capsule?
How should I take Rabepra 20 mg Capsule?
Can I take Rabepra 20 mg Capsule while pregnant or breastfeeding?
What should I do if I overdose on Rabepra 20 mg Capsule?
How long should I take Rabepra 20 mg Capsule?
Is there anything else I should know about Rabepra 20 mg Capsule?
Does Rabepra 20 mg Capsule cause bone problems?
Can I take Rabepra 20 mg Capsule with vitamin D?

Quick Tips

Well-tolerated medicine providing long-term relief
Avoid eating late at night or before bedtime
Inform your doctor if you experience certain symptoms
Long-term use may cause weak bones and deficiency of minerals
Consult your doctor if you develop specific symptoms

Other Information

Studies have been performed in animals and have revealed no evidence of impaired fertility or harm to the fetus due to Rabeprazole, however, there are no adequate and well-controlled studies in pregnant women